Drug Profile
RESP 2000
Alternative Names: RESP-2000Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Respiratorius
- Class Antiasthmatics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Asthma; Chronic obstructive pulmonary disease
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Asthma in Sweden (unspecified route) (Respiratorius pipeline, September 2023)
- 13 Sep 2023 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Sweden (unspecified route) (Respiratorius pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Asthma in Sweden